September 21, 2020

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Mr. Chris Edwards

Re: ADC Therapeutics SA Registration Statement on Form F-1 (File No. 333-248941) Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on Wednesday, September 23, 2020 or as soon thereafter as practicable.

[Signature page follows]

Very truly yours,

Morgan Stanley & Co. LLC

BofA Securities, Inc.

Cowen and Company, LLC

As representatives of the Underwriters

By:	Morgan Stanley & Co. LLC
By:	/s/ Chris Rigoli
	Name:	Chris Rigoli
	Title:	Vice President

By:	BofA Securities, Inc.
By:	/s/ Michael Liloia
	Name:	Michael Liloia
	Title:	Director

By:	Cowen and Company, LLC
By:	/s/ George J. Milstein
	Name:	George J. Milstein
	Title:	Managing Director

[Signature Page to ADC Therapeutics SA Acceleration Request]